GlycoMimetics Inc Cash Flow Conversion Efficiency
GlycoMimetics Inc cash flow conversion efficiency. Based on the latest financial reports, GlycoMimetics Inc (GLYC) has a cash flow conversion efficiency ratio of -1.513x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.11 Billion) by net assets ($3.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GlycoMimetics Inc (2011–2024)
Cash flow conversion efficiency of GlycoMimetics Inc from 2011 to 2024. This chart illustrates how GlycoMimetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for GlycoMimetics Inc for real-time trading data and today's change.
GlycoMimetics Inc Cash Flow Conversion Ratio Explained
GlycoMimetics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GlycoMimetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoMimetics Inc ranked by their cash flow conversion efficiency. Also see GLYC company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Proactis SA
PA:PROAC
|
5.290x |
|
Prairie Provident Resources Inc
TO:PPR
|
0.100x |
|
Niobay Metals Inc
V:NBY
|
-0.432x |
|
Thai Poly Acrylic Public Company Limited
BK:TPA
|
-0.006x |
|
KINGFISH COMPANY EO -01
F:93G
|
N/A |
|
FSBM Holdings Bhd
KLSE:9377
|
-0.082x |
|
Menteng Heritage Realty Tbk PT
JK:HRME
|
-0.001x |
|
Intelicare Holdings Ltd
AU:ICR
|
0.289x |
Annual Cash Flow Conversion Efficiency for GlycoMimetics Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of GlycoMimetics Inc from 2011 to 2024. Review GLYC free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.31 Million | $-31.10 Million | -5.853x | -544.56% |
| 2023-12-31 | $38.41 Million | $-34.88 Million | -0.908x | +16.10% |
| 2022-12-31 | $42.93 Million | $-46.46 Million | -1.082x | -53.61% |
| 2021-12-31 | $81.60 Million | $-57.49 Million | -0.704x | -130.19% |
| 2020-12-31 | $128.22 Million | $-39.24 Million | -0.306x | +9.21% |
| 2019-12-31 | $154.20 Million | $-51.98 Million | -0.337x | -59.85% |
| 2018-12-31 | $205.46 Million | $-43.33 Million | -0.211x | +15.20% |
| 2017-12-31 | $119.70 Million | $-29.77 Million | -0.249x | +70.47% |
| 2016-12-31 | $35.30 Million | $-29.73 Million | -0.842x | -313.57% |
| 2015-12-31 | $40.47 Million | $-8.24 Million | -0.204x | -141.64% |
| 2014-12-31 | $50.80 Million | $-4.28 Million | -0.084x | +98.42% |
| 2013-12-31 | $2.91 Million | $-15.54 Million | -5.345x | -539.33% |
| 2012-12-31 | $12.53 Million | $-10.47 Million | -0.836x | -151.03% |
| 2011-12-31 | $8.46 Million | $13.85 Million | 1.638x | -- |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.